Event Date/Time: Oct 21, 2013 | End Date/Time: Oct 23, 2013 |
Early Registration Date: Aug 09, 2013 |
Description
Cambridge Healthtech Institute (CHI) and the BioPharma Strategy Series bring Executive Decision Making 2013 to Bethesda, MD, October 21-23. The executive forum is made up of back-to-back conferences: Strategic Resource Management and Portfolio Management and brings together key decision makers and industry thought leaders for valuable presentations and discussions on solutions to today’s resource management issues.
Venue
Conference Speakers
- John Ansell, Senior Partner, TranScrip; Author: "Transforming Big Pharma – Assessing the Strategic Alternatives"
- Kathleen Bender, Executive Director, R&D Capacity Management, AstraZeneca
- Brian Bissett, IT Specialist, Office of Systems/CIO, Social Security Administration
- Walter Brooks, Founding Partner, Equinox Group
- Susan Carino, Senior Project Management Consultant, Integrated Project Management
- James Carlson, Senior Director, Program Management and Due Diligence, Shire Regenerative Medicine
- Anastasia Christianson, Ph.D., Senior Director, R&D Information, AstraZeneca
- Philip Fahringer, Operations Analyst, Center for Innovation, Lockheed Martin
- Steven Greidinger, Public-Private Healthcare Ventures
- Arkady Gusev, Ph.D., Head of US Operation, Biomarker Development, Translational Medicine, Novartis
- Miriam Halperin Wernli, Vice President, Deputy Head Global Clinical Development, Global Head Business & Science Affairs, Actelion
- Hartmut Hein, Ph.D., Director, Head of Global Planning Office, Merck Serono (EMD Serono)
- Peter Heinrich, CEO, PDWare
- Keith Hendricks, Vice President, Portfolio Analysis and Assessment, Strategic Initiatives, AbbVie
- Hans Hoogkamer, Head, Lifecycle Portfolio Alignment, Senior Director, Global Business & Science Affairs, Actelion
- Usman Iqbal, M.D., Senior Director, Head of Oncology-Global Evidence & Value Development, sanofi-aventis
- Rafiqul Islam, Senior Director, Global Bioanalytical Services, Celerion, Inc.
- Florian Jehle, Partner, Catenion GmbH
- Shama Kajiji, Ph.D., MBA, Director, Strategy and Portfolio Integration, Janssen Pharmaceuticals R&D
- Jeffrey Keisler, Ph.D., Professor, College of Management, University of Massachusetts Boston
- Jack Kloeber, Ph.D., Principal, KROMITE
- Terence Leddy, Director, CD&S, Portfolio Management, MedImmune
- Sam Mathew, MBA, Portfolio Capacity Leader, PMO/Finance, Janssen Pharmaceutical R&D
- Michael Menard, President, CEO, Executive, GenSight; Author: "A Fish in Your Ear: The New Discipline of Project Portfolio Management"
- Abhishek Mittal, Assistant General Manager, R&D Operations and Project Management, Syngene International Ltd.
- Eric Moss, Director, Portfolio & Decision Analysis, Strategy & Portfolio Management, Pfizer
- Dave Penndorf, Executive Consultant, Planisware USA
- Jan Poth, Ph.D., Vice President, Marketing Pipeline Products, Boehringer Ingelheim
- Frank Rebers, Ph.D., Associate Director, Project Management, Genmab
- George Santangelo, Ph.D., Director, Office of Portfolio Analysis (OPA), Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI), The National Institutes of Health (NIH)
- Jeremy Scully, MBA, Vice President, Global Marketing & Business Development, GenSight
- Kurtis E. Shampine, Vice President & General Manager, ProModel Life Sciences Solutions
- Richard Sonnenblick, Ph.D., CEO, Enrich Consulting
- Alex Stojanovic, Ph.D., Practice Lead - Pharma & Biotech, KROMITE
- Danise Subramaniam, Ph.D., Director, Program Phase Project Management, Eli Lilly & Co.
- Daniel Zweidler, Ph.D., Senior Fellow, Mack Institute for Innovation Management, The Wharton School, University of Pennsylvania